Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by pabalooon Mar 20, 2020 1:53pm

95 Views

Post# 30831212

RE:Watching for a Leak of Q4 Report

I think it's priced in that revenue and earnings are in the same area as last quarter except for the write downs. I don't foresee any blockbuster unless they announce a product sale or resolution to the Trulance abortion. Hope your right and there's interest in the stock. 50 thousand shares right now at market will move this 30 cents.

Bullboard Posts

Opawica seeks drill permits for Bazooka Gold Targets in Abitibi